The University of Wrocław in consortium with the Silesian Park of Medical Technologies Kardio-Med. Silesia will attempt to develop drugs targeting viral RNA. The consortium received over PLN 18 million in the competition of the Medical Research Agency (ABM) in technology development.

The competition projects were either to develop drugs targeting viral RNA – drugs against RNA-based viruses, or to develop an RNA platform to make a vaccine.

– We will not introduce these technologies now, it is not an investment in the current pandemic. We want to secure our country for the future – to react faster and develop these technologies in Poland. This is an investment in the future. We are joining the world avant-garde when it comes to medical research. We are going on an express train that develops RNA technologies, and not a trolley, as is usually the case in Polish biotechnology. The development of this technology is a necessity – says the president of ABM, Dr Radosław Sierpiński.